Edition:
United States

Gilead Sciences Inc (GILD.O)

GILD.O on Nasdaq

70.50USD
27 Feb 2017
Change (% chg)

$0.56 (+0.80%)
Prev Close
$69.94
Open
$69.82
Day's High
$70.54
Day's Low
$69.80
Volume
6,354,158
Avg. Vol
10,514,029
52-wk High
$103.10
52-wk Low
$65.38

GILD.O

Chart for GILD.O

About

Gilead Sciences, Inc. is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company's principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection... (more)

Overall

Beta: 1.15
Market Cap(Mil.): $92,854.30
Shares Outstanding(Mil.): 1,317.46
Dividend: 0.52
Yield (%): 2.95

Financials

  GILD.O Industry Sector
P/E (TTM): 7.09 44.07 29.88
EPS (TTM): 9.94 -- --
ROI: 30.47 -3.76 13.08
ROE: 72.16 5.68 14.24

Gilead seeks to overturn $2.54 bln verdict in hepatitis C drug case

Gilead Sciences Inc has asked a federal judge to overturn a record $2.54 billion jury verdict in a patent infringement lawsuit by rival Merck & Co Inc over Gilead's blockbuster hepatitis C drugs Sovaldi and Harvoni.

Feb 27 2017

BRIEF-Gilead receives approval in Canada for Odefsey for treatment of HIV-1 infection

* Gilead receives approval in Canada for Odefsey for the treatment of HIV-1 infection Source text for Eikon: Further company coverage:

Feb 16 2017

BRIEF-Gilead announces 144-week data evaluating safety and efficacy of Genvoya

* Gilead announces 144-week data evaluating safety and efficacy of Genvoya for treatment of HIV-1 in treatment-naïve adults

Feb 14 2017

Gilead challenges GSK with strong HIV drug data

LONDON Gilead Sciences has thrown down a challenge to GlaxoSmithKline with good clinical trial results for an experimental HIV drug that works in the same way as the British group's successful dolutegravir.

Feb 14 2017

Gilead challenges GSK with strong HIV drug data

LONDON, Feb 14 Gilead Sciences has thrown down a challenge to GlaxoSmithKline with good clinical trial results for an experimental HIV drug that works in the same way as the British group's successful dolutegravir.

Feb 14 2017

BRIEF-Gilead presents new phase 2 data on Bictegravir

* Gilead presents new phase 2 data on Bictegravir, an investigational integrase strand transfer inhibitor for the treatment of HIV

Feb 13 2017

BRIEF-Gilead announces findings from new preclinical study evaluating novel class of HIV Capsid inhibitors

* Gilead announces findings from new preclinical study evaluating novel class of HIV Capsid inhibitors

Feb 13 2017

GlaxoSmithKline and Gilead to face off at HIV meeting next week

LONDON GlaxoSmithKline and Gilead Sciences will vie for business in treating HIV patients next week when both companies unveil clinical trial results at a medical meeting in Seattle.

Feb 08 2017

Gilead shares slump after gloomy sales forecast for hep C drugs

Gilead Sciences Inc's shares fell as much as 10 percent on Wednesday, after the drugmaker forecast bleak sales for its hepatitis C drugs this year, underscoring the need for the company to strengthen its pipeline through acquisitions.

Feb 08 2017

UPDATE 1-Gilead shares slump after gloomy sales forecast for hep C drugs

Feb 8 Gilead Sciences Inc's shares fell as much as 10 percent on Wednesday, after the drugmaker forecast bleak sales for its hepatitis C drugs this year, underscoring the need for the company to strengthen its pipeline through acquisitions.

Feb 08 2017

More From Around the Web

Competitors

Earnings vs. Estimates